Roche Acquiring InterMune for $8.3 billion to Expand Respiratory Product Portfolio

Drug Industry Daily
A A
Swiss pharmaceutical company Roche said yesterday it will acquire California-based biotechnology firm InterMune for $8.3 billion, in a deal that allows Roche to strengthen its respiratory therapy portfolio.

To View This Article:

Login

Subscribe To Drug Industry Daily